Next Article in Journal
Effects of Bofu-Tsusho-San on Diabetes and Hyperlipidemia Associated with AMP-Activated Protein Kinase and Glucose Transporter 4 in High-Fat-Fed Mice
Next Article in Special Issue
MicroRNA-130b Promotes Cell Aggressiveness by Inhibiting Peroxisome Proliferator-Activated Receptor Gamma in Human Hepatocellular Carcinoma
Previous Article in Journal
ZmSOC1, a MADS-Box Transcription Factor from Zea mays, Promotes Flowering in Arabidopsis
Previous Article in Special Issue
Evaluating the Role of PTH in Promotion of Chondrosarcoma Cell Proliferation and Invasion by Inhibiting Primary Cilia Expression
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2014, 15(11), 20004-20021; doi:10.3390/ijms151120004

Validation of Bmi1 as a Therapeutic Target of Hepatocellular Carcinoma in Mice

1
School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
2
Department of Hepatology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
3
Department of Oncology of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 23 August 2014 / Revised: 12 October 2014 / Accepted: 23 October 2014 / Published: 3 November 2014
(This article belongs to the Special Issue Advances in Molecular Oncology 2014)
View Full-Text   |   Download PDF [6783 KB, uploaded 3 November 2014]   |  

Abstract

Bmi1 is a member of the polycomb group family of proteins, and it drives the carcinogenesis of various cancers and governs the self-renewal of multiple types of stem cells. Our previous studies have revealed that Bmi1 acts as an oncogene in hepatic carcinogenesis in an INK4a/ARF locus independent manner. However, whether Bmi1 can be used as a potential target for hepatocellular carcinoma treatment has not been fully confirmed yet. Here, we show that perturbation of Bmi1 expression by using short hairpin RNA can inhibit the tumorigenicity and tumor growth of hepatocellular carcinoma cells both in vitro and in vivo. Importantly, Bmi1 knockdown can block the tumor growth, both in the initiating stages and the fast growing stages. Cellular biology analysis revealed that Bmi1 knockdown induces cell cycle arrest and apoptosis. Our findings verify Bmi1 as a qualified treatment target for hepatocellular carcinoma (HCC) and support Bmi1 targeting treatment with chemotherapeutic agents. View Full-Text
Keywords: Bmi1; HCC; knockdown; proliferation; treatment Bmi1; HCC; knockdown; proliferation; treatment
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Qi, S.; Li, B.; Yang, T.; Liu, Y.; Cao, S.; He, X.; Zhang, P.; Li, L.; Xu, C. Validation of Bmi1 as a Therapeutic Target of Hepatocellular Carcinoma in Mice. Int. J. Mol. Sci. 2014, 15, 20004-20021.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top